The sodium iodide symporter (NIS) as theranostic gene: potential role in pre-clinical therapy of extra-thyroidal malignancies DOI Open Access

Nahid Darabi,

Mohsen Keshavarz, Iraj Nabipour

et al.

Clinical and Translational Imaging, Journal Year: 2023, Volume and Issue: 11(2), P. 113 - 125

Published: Jan. 16, 2023

Language: Английский

EpCAM‐Targeted Erlotinib Delivery: Enhancing Nasopharyngeal Carcinoma Treatment With Polyethylene Glycol‐Coated Graphene Oxide DOI
Chien‐Fu Yeh, Sheng‐Wei Lee,

Chin‐Hsuan Liu

et al.

Head & Neck, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 27, 2025

ABSTRACT Background Recently, graphene oxide (GO) has attracted significant attention as a potential innovative vehicle for the delivery of anticancer agents. In this study, we aimed to evaluate whether functionalized GO, known epithelial cell adhesion molecule (EpCAM)‐targeted polyethylene glycol (PEG)‐coated GO (GO‐PEG‐EpCAM), could be used therapeutic agent against nasopharyngeal carcinoma (NPC) and identify its underlying molecular mechanisms. Methods We NPC cells assess effects GO‐PEG‐EpCAM/erlotinib in vitro vivo. Employing RNA sequencing Ingenuity Pathway Analysis (IPA), sought elucidate pathways through which affects cells. Results Our findings revealed that reduced viability decreased invasion migration abilities. An vivo study further corroborated GO‐PEG‐EpCAM/erlotinib. comprehensive analysis highlighted several mechanisms Conclusions strategy NPC.

Language: Английский

Citations

0
PLGA nanoparticles enhanced cardio-protection of scutellarin and paeoniflorin against isoproterenol-induced myocardial ischemia in rats DOI
Chang Yang, Shanshan Yang,

Shumei Fang

et al.

International Journal of Pharmaceutics, Journal Year: 2023, Volume and Issue: 648, P. 123567 - 123567

Published: Oct. 31, 2023

Language: Английский

Citations

8
Anti-EGFR Targeted Multifunctional I-131 Radio-Nanotherapeutic for Treating Osteosarcoma: In Vitro 3D Tumor Spheroid Model DOI Creative Commons
Suphalak Khamruang Marshall,

Boonyisa Saelim,

Maneerat Taweesap

et al.

Nanomaterials, Journal Year: 2022, Volume and Issue: 12(19), P. 3517 - 3517

Published: Oct. 8, 2022

The systemic delivery of doxorubicin (DOX) to treat osteosarcoma requires an adequate drug concentration be effective, but in doing so, it raises the risk increasing organ off-target toxicity and developing resistance. Herein, this study reveals a multiple therapeutic nanocarrier platform that overcomes by providing good specificity imparting enhanced tumor penetration three-dimensional (3D) human MG-63 spheroid model. By synthesizing PEG-PLGA nanoparticles double emulsion method, encapsulating DOX Na131I inner core, conjugating with epidermal growth factor receptor (EGFR) antibody, is intended specifically target cells. biocompatible blood has stability characteristics. encapsulation efficiency was >96%, radiochemical purity >96% over 96 h. A efficacy ~80% achieved, loading ~3%, sustained release 5 days. EGFR antibody achieved ~80-fold greater targeting cells (EGFR+) than fibroblast (EGFR−). targeted DIE-NPs have higher uptake 3D model ~3-fold cytotoxicity monotherapy (D-NPs). co-administration (DIE-NPs) disrupts DNA repair generates free radicals resulting damage, triggering activation apoptosis pathways. This leads inhibition cell proliferation promotes cycle arrest G0/G1 phase. Furthermore, PEGylated anti-EGFR functionalized were found red no adverse effects. multifunctional I-131 radio-nanotherapeutic signifies customizable specific treatment for osteosarcoma.

Language: Английский

Citations

12
Smart Targeted-Nanocarriers for Cancer Therapeutics DOI
Débora Ferreira, Renata Silva, Laura Figueiredo

et al.

Environmental science and engineering, Journal Year: 2024, Volume and Issue: unknown, P. 377 - 407

Published: Jan. 1, 2024

Language: Английский

Citations

1
Evaluation of Single Dose and Fractionated Dose of I-131 Radiolabeled Nanoparticles for Triple-Negative Breast Cancer Treatment DOI Creative Commons
Suphalak Khamruang Marshall,

Nutnicha Kaewpradit,

Tavadee Mudmarn

et al.

Biomedicines, Journal Year: 2023, Volume and Issue: 11(8), P. 2169 - 2169

Published: Aug. 1, 2023

Combination chemotherapy is still the standard clinical care for triple-negative breast cancer (TNBC). However, sodium iodide symporter (NIS) uptake by TNBC has opened potential of NIS as a molecular target radioiodine theranostic treatments. Radiolabeled poly(lactic-co-glycolic) acid nanocarrier (NINP) was developed targeted delivery I-131 to MDA-MB-231 cells overcome low in and rapid clearance. The NINP diameter 237 nm good particle size uniformity excellent stability. Radiochemical purity, radioactive stability, radiolabeling yield NINPs over 72 h were >95%. Cytotoxicity confirmed fractionated be more effective cell death than single-dose both single Na131I. Cellular three-dimensional spheroid that fractionated-dose achieved ~4.8-fold-higher mean fluorescent intensity Na131I ~2.7-fold greater reduction viability compared single-dose. initiated cellular DNA damage NINP, resulting inhibition cycle progression, progression being inhibited cyclin-dependent kinases, which play vital role control cycle. are biocompatible with blood, found have no negative impact on red blood cells.

Language: Английский

Citations

3
The sodium iodide symporter (NIS) as theranostic gene: potential role in pre-clinical therapy of extra-thyroidal malignancies DOI Open Access

Nahid Darabi,

Mohsen Keshavarz, Iraj Nabipour

et al.

Clinical and Translational Imaging, Journal Year: 2023, Volume and Issue: 11(2), P. 113 - 125

Published: Jan. 16, 2023

Language: Английский

Citations

0